Clinical Trial Update: GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC

View source ↗

Summary

A clinical trial is evaluating a combination regimen of GEMOX-HAIC plus GEM-SYS with Lenvatinib and a PD-1 inhibitor for large unresectable intrahepatic cholang…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• GEM-SYS
• GEMOX-HAIC
• Lenvatinib (lenvatinib)
• PD-1 inhibitor

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Intrahepatic Cholangiocarcinoma | Status: RECRUITING